Research programme: schizophrenia therapeutics - EUSA Pharma
Alternative Names: TKP-1002Latest Information Update: 18 Jun 2012
At a glance
- Originator EUSA Pharma
- Class
- Mechanism of Action
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Schizophrenia
Most Recent Events
- 18 Jun 2012 Discontinued - Preclinical for Schizophrenia in United Kingdom (unspecified route)
- 09 Oct 2007 EUSA Pharma is seeking partnership/divestment opportunities for TKP 1002 in Schizophrenia (http://www.eusapharma.com)
- 09 Oct 2007 Preclinical trials in Schizophrenia in United Kingdom (unspecified route)